首页> 外文期刊>Modern Pathology >Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH)
【24h】

Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH)

机译:HER2状态确定对胸针活检的准确性(免疫组化,FISH,CISH和SISH与FISH)

获取原文
           

摘要

Preoperative breast cancer diagnosis on core biopsies has become a standard of care in many countries. Controversies exist concerning the accuracy of HER2 testing on biopsies as compared with surgical specimens, and few data exist concerning the use of emerging technologies such as bright-field in-situ hybridization in such a setting. A French multicenter, cross-sectional, histopathological study assessed the concordance of HER2 status determined by immunohistochemistry and silver (SISH) or chromogenic in-situ hybridization (CISH) on core-needle biopsies with HER2 status determined by fluorescence in-situ hybridization (FISH) on surgical specimens. The concordance between biopsy and operative results was also assessed for each method. We studied 260 breast tumors from 24 centers between April 2003 and August 2009. Excellent concordance (κ: 0.92–0.97) was shown between immunohistochemistry and FISH with low discordance rates (2–4%), high specificity (97–98%) and sensitivity values (95–99%), with no significant difference according to the immunohistochemistry interpretation guidelines used. The correlation between SISH and CISH on biopsies and FISH on surgical samples was strong (κ: 0.96 and 0.94, respectively), with no significant difference between false negative rates or sensitivity and specificity values (2 and 5%, 99 and 96%, 98 and 98%, respectively). Whatever the evaluation technique, excellent concordance between biopsies and surgical specimens was observed (κ 0.97; discordance rates between 1 and 2%), with high sensitivity (98–99%) and specificity (98–100%). Based on these results, when FISH cannot be used, SISH and/or CISH could be proposed as an alternative method to determine HER2 status and to confirm any ambiguous immunohistochemistry results, either for preoperative percutaneous biopsies or for surgical specimens. They could also be used for quality controls and immunohistochemistry calibration.
机译:在许多国家,对核心活检进行术前乳腺癌诊断已成为一种护理标准。与手术标本相比,存在关于活检组织中HER2检测准确性的争议,关于在这种情况下使用诸如明视野原位杂交等新兴技术的数据很少。一项法国多中心,横断面,组织病理学研究评估了通过免疫组织化学和银(SISH)或发色原位杂交(CISH)确定的HER2状况与荧光原位杂交(FISH)确定的HER2状况的一致性)在手术标本上。每种方法还评估了活检与手术结果之间的一致性。我们研究了2003年4月至2009年8月间来自24个中心的260个乳腺肿瘤。免疫组化和FISH之间显示出极好的一致性(κ:0.92-0.97),不一致率低(2-4%),特异性高(97-98%) )和灵敏度值(95–99 %),根据所使用的免疫组织化学解释指南,无明显差异。活检组织上的SISH和CISH以及手术样本上的FISH之间的相关性很强(分别为κ:0.96和0.94),假阴性率或敏感性和特异性值之间无显着差异(2和5 %,99和96 % ,分别为98和98 %)。无论采用哪种评估技术,都可以观察到活组织检查与手术标本之间的出色一致性(κ0.97;不一致率在1-2%之间),具有很高的灵敏度(98–99%)和特异性(98–100%)。基于这些结果,当不能使用FISH时,可以提议SISH和/或CISH作为确定HER2状态并确认任何歧义的免疫组化结果的替代方法,无论是术前经皮活检还是手术标本。它们也可以用于质量控制和免疫组织化学校准。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号